1. Pfizer Earnings Were Not Impressive http://www.trefis.com/stock/pfe/articles/262515/pfizer-earnings-were-not-impressive/2014-10-29 by Trefis Team $PFE $MRK $RHHBY

  2. Bristol-Myers Squibb Rises On Earnings Boost http://www.trefis.com/stock/bmy/articles/261967/bristol-myers-squibb-rises-on-earnings-boost/2014-10-27 by Trefis Team $BMY $MRK $RHHBY

  3. Bristol-Myers Squibb Earnings Preview: What We Are Watching http://www.trefis.com/stock/bmy/articles/261289/bristol-myers-squibb-earnings-preview-what-we-are-watching-24-oct/2014-10-22 by Trefis Team $BMY $MRK $RHHBY

  4. Roche s Cancer Drug Sales Continue To Grow, May Face Competition In Medium Term http://www.trefis.com/stock/rhhby/articles/259867/roches-cancer-drug-sales-continue-to-grow-may-face-competition-in-medium-term/2014-10-21 by Trefis Team $RHHBY $PFE $MRK

  5. Weekly Pharma Notes: Pfizer, Bristol-Myers Squibb, Johnson & Johnson, Merck And Roche http://www.trefis.com/stock/pfe/articles/259484/weekly-pharma-notes-pfizer-bristol-myers-squibb-johnson-johnson-merck-and-roche/2014-10-13 by Trefis Team $BMY $JNJ $MRK

  6. Bristol Myers Squibb Getting Close To Lung Cancer Approval For Nivolumab http://www.trefis.com/stock/bmy/articles/258364/bristol-myers-squibb-getting-close-to-lung-cancer-approval-for-nivolumab/2014-10-02 by Trefis Team $BMY $MRK $RHHBY

  7. What Is InterMune s Revenue Potential For Roche? http://y.ahoo.it/N5da9H9A by Trefis Team $RHHBY $JNJ $PFE

  8. Weekly Pharma Notes: Bristol-Myers Squibb, Johnson & Johnson, Merck And Roche http://y.ahoo.it/OnViRGME by Trefis Team $BMY $JNJ $MRK

  9. Weekly Pharma Notes: Bristol-Myers Squibb, Pfizer, Merck And Roche http://y.ahoo.it/GKX45bDf by Trefis Team $BMY $MRK $PFE

  10. Roche s Sales Inch Up Slowly And Steadily http://y.ahoo.it/JeophcLo by Trefis Team $RHHBY

  11. Roche Earnings Preview: Continued Adoption For Key Cancer Drugs Will Drive Growth ... http://y.ahoo.it/BxoAlyLY by Trefis Team $RHHBY $PFE $MRK

  12. Johnson & Johnson Earnings Preview: Pharma Buisness To Remain Strong http://y.ahoo.it/nXS3jhGm by Trefis Team $JNJ $RHHBY $PFE

  13. Johnson & Johnson s Growth Avenues http://y.ahoo.it/IovlPmMp by Trefis Team $JNJ $PFE $RHHBY

  14. What If Legacy Pharmaceutical & Consumer Business Keeps Falling For Merck? http://y.ahoo.it/RYR72hif by Trefis Team $MRK $BMY $RHHBY

  15. Pfizer s Plan B In Immuno-Oncology: Collaboration With Smaller Companies http://y.ahoo.it/w1qZsoMe by Trefis Team $PFE $MRK $RHHBY

  16. Roche s Purchase Of Genia Is A Long Term Move http://y.ahoo.it/94wnNNgu by Trefis Team $RHHBY $JNJ $ABT

  17. Why Did Merck Pay Such A Huge Premium For Idenix http://y.ahoo.it/9TctWyjJ by Trefis Team $MRK $RHHBY $BMY

  18. What Merck, Bristol-Myers Squibb And Roche Are Doing To Win The Immuno-Oncology Dr... http://y.ahoo.it/TJWLGW6F by Trefis Team $MRK $BMY $RHHBY

  19. Roche Reaffirms Full Year Outlook But Suffers From Currency Movements (publish tod... http://y.ahoo.it/aUTOLE6w by Trefis Team $RHHBY $PFE $MRK

  20. Roche s Competitive Advantage http://y.ahoo.it/XogppqqU by Trefis Team $RHHBY $PFE $MRK

  21. The Breakthrough Biotech That’s Up 500% . . . And Counting http://y.ahoo.it/ZM5G9iMB $INO $PFE $RHHBY

  22. $RHHBY will begin trading ex-dividend on March 6, 2014 and will pay out a dividend of 0.693601 cents for each share - http://y.ahoo.it/4UvdJHoW

  23. Bristol-Myers Squibb Earnings Preview: Immuno-Oncology Drugs In Focus http://y.ahoo.it/Kq6qHjdh by Trefis Team $BMY $MRK $RHHBY

  24. Shopping for Biotech Growth Names: Reni Benjamin http://y.ahoo.it/iNYNGlE7 $BMY $MRK $RHHBY

  25. PSivida: An Extremely Undervalued Ophthalmology Small Cap Investment With Upcoming Catalyst http://y.ahoo.it/CT9ABEXA $PFE $RHHBY $GSK